APUS Apimeds Pharmaceuticals Earnings per share increase in current year

Apimeds Pharmaceuticals (APUS) develops innovative bee venom-based pain relief treatments. Business development is tied to lengthy clinical trial stages, ignoring general market trends. However, success depends on FDA approval and the influx of investment. On GURU.Markets, the annual growth rate of net income per share demonstrates cost management efficiency, with the current value standing at 0.00.

Earnings per share growth in current year: Apimeds Pharmaceuticals, Inc. (APUS) for 05/10/2025 - 11/14/2026

Financial and market metric breakdowns for apimedsus.com (APUS)

- market value and analyst target forecast:

Stock Price Apimeds Pharmaceuticals US|APUS - Price Target Chart

- market capitalization data:

Market Value Apimeds Pharmaceuticals, Inc.|APUS - Total Company Value

- business book valuation details:

Net Asset Value per Share Apimeds Pharmaceuticals|APUS - Company Book Value|Market Value to Book Value Ratio apimedsus.com|APUS - Aggregate Company Assets

- debt and liquidity details:

- company profitability and valuation multiples indicators:

APUS - Net Profit|Company Profit Forecast Apimeds Pharmaceuticals|APUS - Price to Earnings Ratio|Projected Price to Earnings Apimeds Pharmaceuticals US|APUS - PEG Multiple|Company Value to EBITDA Apimeds Pharmaceuticals, Inc.|APUS - Operating profit EBITDA|Earnings per share for the last 12 months Apimeds Pharmaceuticals|APUS - Earnings per share for the last twelve months|Year-over-year net earnings per share change for the last twelve months apimedsus.com|APUS - Net earnings per share growth this year|Expected earnings per share trend next year Apimeds Pharmaceuticals

- revenue and sales proceeds data:

APUS - Company Revenue|Company Expected Revenue Apimeds Pharmaceuticals US|APUS - P/S Multiple|Forward Price to Sales Apimeds Pharmaceuticals, Inc.

Summary company analysis:APUS Apimeds

Signature product of Apimeds Pharmaceuticals US

Defensive assets are selected based on the criterion of stable growth in real business efficiency. Apimeds Pharmaceuticals (APUS) aligns with this approach, focusing on the preparation of FDA documentation and the completion of clinical trials. This metric measures the year-over-year percentage change in earnings per share, excluding market noise. By analyzing the annual trajectory of earnings per share, an investor assesses the resilience of the operating model. Current R&D expenses are already priced in.

Direct competitors